Chris Ryan on Muck Rack

Chris Ryan

Verified
New Jersey
As seen in: MJH Life Sciences, OncLive, MSN, NJ.com, The Star-Ledger, Health, Penn Live Patriot-News, SPIN, Lehigh Valley Live, Staten Island Advance, Syracuse.com, NewsBreak and
Managing Editor, @OncLive. Noted tall person. Recovering sports reporter. Past: @njdotcom. I know way too much about the Devils.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chris

Contact Chris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma

|
By Alex Herrera, Álex Herrera, Kristen D. Brantley, Chris Ryan 
| ONCOLOGY journal
Early studies identifying a signal with PD-1 blockade in patients with advanced Hodgkin lymphoma being treated in the frontline setting inspired the development of the phase 3 SWOG S1826 trial (NCT03907488), according to Alex Herrera, MD.1 In a conversation with CancerNetwork®, Herrera, chief of the Division of Lymphoma in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope as well as associate medical director of the Briskin Center for Clinical Research,...
Open in Who Shared Issue with article?

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

|
By Chris Ryan , Ashling Wahner , Russ Conroy
| ONCOLOGY journal
Objective responses and minimal residual disease (MRD) negativity occurred in all patients who received ciltacabtagene autoleucel (cilta-cel; Carvykti) for high-risk smoldering multiple myeloma, according to data from the from the phase 2 CAR-PRISM trial (NCT05767359) presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and published in Nature Medicine.1,2 Findings demonstrated that among patients evaluable for response (n = 20), a best response of complete...
Open in Who Shared Issue with article?

Venetoclax-Based RIC Transplant and Maintenance Is Feasible in Poor-Risk MDS and AML

|
By Chris Ryan , Riley Kandel, Kirsty Mackay
| AAMDSIF Podcasts for Patients
Posttransplant maintenance with venetoclax (Venclexta) plus decitabine (Dacogen) and cedazuridine (Inqovi) following a reduced-intensity conditioning (RIC) transplant regimen of venetoclax plus fludarabine and busulfan (FluBu2), along with tacrolimus (Prograf) plus methotrexate graft-vs-host disease (GVHD) prophylaxis, was safe and efficacious in patients with poor-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), according to data from a phase 1 trial (NCT03613532).1...
Open in Who Shared Issue with article?
See all 2,510 licensed articles (4,460 Total)

Actions

Share this page

Get in touch with Chris

Contact Chris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified